GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Get Free Report) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 38,100 shares, a drop of 25.7% from the May 15th total of 51,300 shares. Based on an average daily trading volume, of 12,100 shares, the days-to-cover ratio is currently 3.1 days. Approximately 0.1% of the shares of the company are sold short.
GENFIT Trading Down 3.8%
Shares of GNFT traded down $0.16 during midday trading on Friday, reaching $3.89. 2,759 shares of the stock were exchanged, compared to its average volume of 10,655. GENFIT has a twelve month low of $2.55 and a twelve month high of $6.42. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.08. The stock's 50 day simple moving average is $4.09 and its 200 day simple moving average is $3.80.
Institutional Investors Weigh In On GENFIT
An institutional investor recently bought a new position in GENFIT stock. Millennium Management LLC bought a new position in shares of GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 166,375 shares of the company's stock, valued at approximately $611,000. Millennium Management LLC owned approximately 0.33% of GENFIT as of its most recent filing with the Securities & Exchange Commission. 2.24% of the stock is currently owned by institutional investors and hedge funds.
GENFIT Company Profile
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
Before you consider GENFIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GENFIT wasn't on the list.
While GENFIT currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
